Clinical Trial Detail

NCT ID NCT04230304
Title Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Daratumumab + Ibrutinib

Age Groups: adult senior

No variant requirements are available.